Lack of Efficacy of Psychological and Pharmacological Treatments of Eating Disorders: Neurobiological Background
Overview
- Phase
- Not Applicable
- Intervention
- CBT (Cognitive Behavioral Therapy)
- Conditions
- Anorexia Nervosa
- Sponsor
- University of Turin, Italy
- Enrollment
- 112
- Locations
- 1
- Primary Endpoint
- change in brain secretion of Dopamine at 6 months
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Background. Treatments of eating disorders result too often in partial psychological and physical remission, chronic course, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted a three branches study to identify the biochemical background of cognitive-behavioral psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT+olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3 Hydrogen]-Paroxetine-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations. Methods. Branch 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3 Hydrogen]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Branch 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Branch 3 investigated the effect of 3 months of CBT+olanzapine (5 mg/day) in 30 AN outpatients. The data are analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.
Investigators
Federico Amianto
Dottor
University of Turin, Italy
Eligibility Criteria
Inclusion Criteria
- •eating disorders full diagnosis according to Diagnostic and Statistical Manual (DSM-IV)
- •age between 15 and 35
- •female gender
Exclusion Criteria
- •associated major psychiatric problems
- •mental retardation
Arms & Interventions
CBT (Cognitive Behavioral Therapy)
Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: CBT (Cognitive Behavioral Therapy)
CBT (Cognitive Behavioral Therapy)
Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: nutritional rehabilitation
CBT (Cognitive Behavioral Therapy)
Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: delorazepam
IBPP (IP brief psychotherapy )
Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation.
Intervention: IBPP (individual psychology brief psychotherapy)
IBPP (IP brief psychotherapy )
Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation.
Intervention: nutritional rehabilitation
IBPP (IP brief psychotherapy )
Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation.
Intervention: delorazepam
CBT + OLANZAPINE (5 MG)
The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: CBT + OLANZAPINE
CBT + OLANZAPINE (5 MG)
The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: nutritional rehabilitation
CBT + OLANZAPINE (5 MG)
The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA. Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation
Intervention: delorazepam
Outcomes
Primary Outcomes
change in brain secretion of Dopamine at 6 months
Time Frame: 6 months
plasma homovanillic acid (HVA) measured before and after the therapeutic intervention in each branch.
change in brain secretion of Noradrenaline at 6 months
Time Frame: 6 months
plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) measured before and after the therapeutic intervention in each branch
change in brain secretion of serotonin at 6 months
Time Frame: 6 months
the platelet paroxetine binding (\[3 Hydrogen\]-Par-binding): Bmax (maximum binding capacity) and Kd (dissociation constant) measured before and after the therapeutic intervention in each branch.
Secondary Outcomes
- Depressive Psychopathology improvement after 6 months(6 months)
- Impulsiveness improvement after 6 months(6 months)
- Eating Psychopathology improvement after treatments at 6 months(6 months)
- Anxiety improvement after 6 months(6 months)
- Self-rated Biochemical improvement after 6 months(6 months)
- Personality improvement after 6 months(6 months)